Want to see FR:IPN full AI Analyst Report?
Top Page
Ipsen
(IPN)
Select Model
Select Model
Rating:67Neutral
Price Target:
€186.00
▲(14.96% Upside)
Action:Downgraded
Date:02/23/26
The score is driven by solid underlying financial performance (growth with still-healthy profitability and manageable leverage), supported by a strong uptrend in price. These positives are tempered by stretched technical momentum (RSI/Stoch elevated), margin compression and higher debt in 2025, and a relatively high P/E with a low dividend yield.
Positive Factors
Steady Revenue Growth & Profitability
Sustained multi-year top-line growth with a ~30% EBITDA margin indicates a scalable specialty-biopharma model and durable demand for marketed therapies. Over 2–6 months this underpins cash generation, reinvestment capacity, and supports continued commercial and R&D investment.
Negative Factors
Meaningful Margin Compression
A sustained decline in net margins versus prior years suggests persistent cost pressures, pricing/reimbursement headwinds, or adverse product mix. Over months this reduces incremental returns on new investments, compresses internal funding for R&D, and limits profit resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth & Profitability
Sustained multi-year top-line growth with a ~30% EBITDA margin indicates a scalable specialty-biopharma model and durable demand for marketed therapies. Over 2–6 months this underpins cash generation, reinvestment capacity, and supports continued commercial and R&D investment.
Read all positive factors
Ipsen (IPN) vs. iShares MSCI France ETF (EWQ)
Market Cap
€13.46B
Dividend Yield1.17%
Average Volume (3M)64.26K
Price to Earnings (P/E)29.9
Beta (1Y)0.57
Revenue Growth8.10%
EPS Growth28.14%
CountryFR
Employees5,535
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)5.37
Shares Outstanding83,814,530
10 Day Avg. Volume52,964
30 Day Avg. Volume64,259
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€164.80Price Target Upside1.85% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)13.07
Revenue Forecast (FY)€4.25B
Ipsen Business Overview & Revenue Model
Company Description
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; ...
How the Company Makes Money
Ipsen makes money primarily by selling prescription medicines through its Specialty Care business. Revenue is largely generated from product sales of its marketed drugs to wholesalers, hospitals, pharmacies, and healthcare providers (depending on ...
Ipsen Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.68B | 3.57B | 3.31B | 3.16B | 2.75B |
| Gross Profit | 2.59B | 2.96B | 2.74B | 2.63B | 2.31B |
| EBITDA | 1.10B | 1.16B | 1.14B | 1.13B | 1.06B |
| Net Income | 444.50M | 345.90M | 644.40M | 648.60M | 646.60M |
Balance Sheet | |||||
| Total Assets | 6.94B | 6.44B | 6.32B | 5.61B | 4.99B |
| Cash, Cash Equivalents and Short-Term Investments | 1.53B | 679.20M | 528.40M | 1.17B | 814.70M |
| Total Debt | 867.10M | 426.80M | 462.90M | 771.60M | 786.60M |
| Total Liabilities | 2.60B | 2.26B | 2.50B | 2.27B | 2.25B |
| Stockholders Equity | 4.34B | 4.18B | 3.83B | 3.34B | 2.74B |
Cash Flow | |||||
| Free Cash Flow | 1.03B | 133.00M | 749.70M | 700.30M | 453.90M |
| Operating Cash Flow | 1.14B | 915.50M | 865.90M | 953.20M | 871.80M |
| Investing Cash Flow | -615.20M | -676.60M | -1.07B | -458.60M | -332.00M |
| Financing Cash Flow | 298.40M | -100.00M | -458.40M | -146.00M | -400.30M |
Ipsen Technical Analysis
Neutral
161.80
Price Trends
160.81
Positive
159.45
Positive
141.97
Positive
Market Momentum
2.42
Negative
49.13
Neutral
40.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:IPN, the sentiment is Neutral. The current price of 161.8 is below the 20-day moving average (MA) of 163.32, above the 50-day MA of 160.81, and above the 200-day MA of 141.97, indicating a neutral trend. The MACD of 2.42 indicates Negative momentum. The RSI at 49.13 is Neutral, neither overbought nor oversold. The STOCH value of 40.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:IPN.
Ipsen Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €13.46B | 29.91 | 10.82% | 1.17% | 8.10% | 28.14% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | €10.71B | -24.87 | ― | ― | ― | ― | |
46 Neutral | €1.80B | -68.51 | ― | ― | ― | ― | |
43 Neutral | €53.69M | -17.63 | ― | ― | 9.51% | 73.33% | |
42 Neutral | €844.20M | -3.30 | -241.12% | ― | ― | 27.51% | |
42 Neutral | €413.24M | -2.80 | -58.93% | ― | -15.98% | -54.34% |
* General Sector Average
FR:IPN
Ipsen
160.60
55.81
53.26%
FR:ABVX
Abivax SA
120.10
112.81
1547.46%
FR:DBV
DBV Technologies
2.81
1.10
64.06%
FR:NANO
Nanobiotix
34.94
30.50
686.94%
FR:VLA
Valneva
2.27
-0.34
-13.16%
FR:AB
AB Science SA
0.69
-0.64
-47.89%
Ipsen Corporate Events
Ipsen’s corabotase shows prolonged effect and high satisfaction in phase II glabellar lines trial
May 17, 2026
Ipsen reported phase II data for its first‑in‑class recombinant neuro‑inhibitor corabotase in patients with moderate to severe glabellar lines, showing a rapid onset of action, superior peak effect to placebo and stronger wrinkle...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.